Report
Quarterly Litigation Status Report-March 2015
Date
File
Quarterly Litigation Status Report (March 2015)
(213.03 KB)
Displaying 2821 - 2840 of 4976
FTC Approves Surgery Center Holdings, Inc.’s Application to Divest Assets in Central Florida to Dr. Mark W. Hollmann
Date
Following a public comment period, the Federal Trade Commission has approved an application from the owners of Surgery Center Holdings, known as Surgery Partners to divest Symbion Holdings Corporation...
H.I.G. Bayside Debt, et al., In the Matter of
The FTC required Surgery Center Holdings, Inc., known as Surgery Partners, and Symbion Holdings Corporation, to divest Symbion’s ownership interest in an ambulatory surgery center in Orange City, Florida to Dr. Mark W. Hollmann, as part of a settlement resolving charges that Surgery Partners’ $792 million purchase of Symbion would be anticompetitive. Both companies operate a large number of ambulatory surgery centers located throughout the country that sell and provide outpatient surgical services to commercial health plans and commercially insured patients. The proposed merger would have combined the only two multi-specialty ambulatory surgical centers in the Orange City/Deltona area of Florida, and would have left commercial health plans and commercially insured patients there with only one meaningful alternative to Surgery Partners’ outpatient surgical services.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
141 0183
C-4494
Statement by FTC Chairwoman Edith Ramirez on U.S. Supreme Court Ruling Regarding North Carolina Dental Board Matter
Date
“Today, the Supreme Court affirmed the FTC's position in recognizing that a state may not give private market participants unsupervised authority to suppress competition even if they act through a...
Feb24
Examining Health Care Competition
-
The Federal Trade Commission and U.S. Department of Justice, Antitrust Division held a public workshop on February 24-25, 2015, as part of the workshop series, “Examining Health Care Competition,” to...
1503003 Informal Interpretation
Date
Rule
Form 4(d) question
You are correct - you would not produce documents related to non-merger specific synergies
File
Original Image File
(70.66 KB)
1502004 Informal Interpretation
Date
Rule
Form Item 4(d)
You are correct- you would not produce documents related to non-merger specific synergies.
File
Original Image File
(122.71 KB)
FTC Puts Conditions on Novartis AG’s Proposed Acquisition of GlaxoSmithKline’s Oncology Drugs
Date
Global pharmaceutical company Novartis AG has agreed to divest all assets related to its BRAF and MEK inhibitor drugs, currently in development, to Boulder, Colorado-based Array BioPharma to settle...
Boehringer Ingelheim Pharmaceuticals, Inc.
Type of Action
Process Enforcement
Last Updated
FTC Matter/File Number
091 0182
Case Status
Closed
Zillow, Inc. and Trulia, Inc.
Date
Matter Number
141 0214
File
File
Closing Letter To Counsel For Trulia, Inc.
(20.09 KB)
Statement of Commissioner Ohlhausen, Commissioner Wright, and Commissioner McSweeny Concerning Zillow, Inc/Trulia, Inc
Date
By
Maureen K. Ohlhausen, Former Commissioner and Former Acting Chair;
Joshua D. Wright, Former Commissioner;
Terrell McSweeny, Former Commissioner
Matter Number
141 0214
FTC Challenges Proposed Merger of Sysco and US Foods
Date
Agency Charges Merger Would Create a National Broadline Foodservice Distributor With 75 Percent Market Share, and Harm Customers in Numerous Local Markets
FTC, DOJ Announce Agenda for Joint Public Workshop on Examining U.S. Health Care Competition
Date
The Federal Trade Commission and the U.S. Department of Justice’s Antitrust Division have issued an agenda and posted speaker bios for their joint workshop in the series Examining Health Care...
1502003 Informal Interpretation
Date
Rule
USC 18a(c)(2) – 7A(c)(2)
Without the associated mortgages, the acquisition of the origination platform is not exempt under 7A(c)(2).
File
Original Image File
(160.08 KB)
FTC Approves Merck & Co., Inc.’s Application to Sell Facilities for Manufacturing Heartgard and Heartgard Plus Heartworm Treatments for Dogs to Merial
Date
Following a public comment period, the Federal Trade Commission has approved an application for prior approval from Merck & Co., Inc. to sell its Barcelonata facility to Merial Barceloneta LLC, a...
Schering-Plough Corporation, , In the Matter of
The Commission challenged Schering-Plough’s proposed $41.4 billion acquisition of Merck & Co., and required divestitures to preserve competition in markets for human and animal pharmaceuticals. The proposed consent order requires that Merck sell its interest in Merial Limited, an animal health joint venture with Sanofi-Aventis S.A., and that Schering-Plough sell its assets related to significant drugs for nausea and vomiting in humans.
Type of Action
Administrative
Last Updated
FTC Matter/File Number
091 0075
Docket Number
C-4268
Statement by FTC Chairwoman Edith Ramirez on Appellate Ruling in the St. Luke’s Hospital Matter
Date
The decision affirms the decision by the U.S. District Court in the District of Idaho, which held that the acquisition violated Section 7 of the Clayton Act and the Idaho Competition Act, and ordered...
1502002 Informal Interpretation
Date
Rule
UPE
Client X would not be able to rely on its Company A HSR.
File
Original Image File
(191.73 KB)
FTC Submits Fiscal Year 2016 Budget Request, Performance Plan, and Fiscal Year 2014 Performance Report to Congress
Date
The Federal Trade Commission has submitted to Congress its Fiscal Year 2016 budget request, which includes the FY 2016 Budget Overview Statement, Performance Plan for FY 2015 and FY 2016, and...
Displaying 2821 - 2840 of 4976